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Available online 1 December 2015Mice deﬁcient in intestinal alkaline phosphatase (IAP) develop type 2 diabetes mellitus (T2DM). We hypothe-
sized that a high level of IAPmight be protective against T2DM in humans.Wedetermined IAP levels in the stools
of 202 diabetic patients and 445 healthy non-diabetic control people.We found that compared to controls, T2DM
patients have approx. 50% less IAP (mean +/− SEM: 67.4 +/− 3.2 vs 35.3 +/− 2.5 U/g stool, respectively; p b
0.000001) indicating a protective role of IAP against T2DM.Multiple logistic regression analyses showed an inde-
pendent association between the IAP level and diabetes status. With each 25 U/g decrease in stool IAP, there is a
35% increased risk of diabetes. The study revealed that obese people with high IAP (approx. 65 U/g stool) do not
develop T2DM. Approx. 65% of the healthy population have b 65.0 U/g stool IAP, and predictably, these people
might have ‘the incipient metabolic syndrome’, including ‘incipient diabetes’, and might develop T2DM and
other metabolic disorders in the near future. In conclusion, high IAP levels appear to be protective against diabe-
tes irrespective of obesity, and a ‘temporal IAP proﬁle’ might be a valuable tool for predicting ‘the incipient
metabolic syndrome’, including ‘incipient diabetes’.









Type 2 diabetes mellitus (T2DM) is characterized by hyperglyce-
mia, and it is a major global health problem that affects nearly 5.3%
population of the world with devastating consequences in the con-
text of healthcare cost, morbidity and mortality. T2DM causes long-
term damage, dysfunction, and failure of different organs, especially
the eyes, kidneys, nerves, heart, and blood vessels (American Diabe-
tes Association, 2014; Abdullah et al., 2014; Kahn et al., 2014). It is a
major global health problem that affected 387 million people world-
wide in 2014 and cost 612 billion US dollars (Abdullah et al., 2014).
In the United States, estimated 24.4 million people (9.2% population)
had diabetes in 2013, costing 306 billion dollars (Abdullah et al.,
2014).
Etiologically, various factors have been postulated to be involved
in the development of T2DM, such as autoimmunity, the metabolicass index; FPG, fasting plasma
O, IAP knockout; L-Arg, L-
ccharides; TNAP, tissue non-
.
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. This is an open access article undersyndrome, diets, obesity, infection, ethnicity, genetic polymorphism
and predisposition, drugs, stress, sedentary lifestyle, pregnancy, etc.
(Velloso et al., 2013; Kahn et al., 2014; Stumvoll et al., 2005; Masters
et al., 2011). Recently, a low-grade systemic inﬂammation, induced
by persistently increased levels of endotoxin lipopolysaccharides
(LPS) in blood (metabolic endotoxemia), has been implicated as an
etiological factor for T2DM (Cani et al., 2007). In our previous
work, we have shown that mice deﬁcient in the brush-border en-
zyme intestinal alkaline phosphatase (IAP) (Akp3 knockout,
Akp3−/−) develop T2DM (Kaliannan et al., 2013). We have also
shown that IAP detoxiﬁes LPS and reduces metabolic endotoxemia,
and oral supplementation with IAP not only prevents but also cures
high-fat diet-induced T2DM in wild-type mice (Kaliannan et al.,
2013). Because IAP deﬁciency results in T2DM in mice, we hypothe-
sized that a high level of IAP might play a protective role against
T2DM in humans. Therefore, using a case-control design we recruit-
ed T2DM and non-T2DM subjects from a community in the suburb of
Dhaka, Bangladesh, and determined the levels of IAP in the stools of
these participants. Here, we report that people with diabetes have
less amounts of IAP in their stool compared to their healthy counter-
parts. Also, we found that obese people with high IAP do not develop
T2DM. Further, results of this study suggest that ‘temporal IAP proﬁl-
ing’ might be a valuable tool for identifying ‘incipient’ T2DM and
other metabolic disorders.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Study Design and Participants
A case-control studywas used to assess the difference in the concen-
trations of IAP in stools of diabetic and control healthy populations. Par-
ticipants, aged 30–70 yr., were recruited from a suburban community of
Dhaka, Bangladesh by advertisement through local dignitaries, hospi-
tals, clinics and physicians' ofﬁces. Based on preliminary data (unpub-
lished) the sample size of each group was calculated to achieve
statistical power of 80% or more (continuous endpoint, α= 0.05). The
study included 202 diabetic cases (63 males and 139 females) and 445
healthy control subjects (114 males and 331 females) of the same eth-
nicity. The study included more females than males just because of
more accessibility to female participants. People with T2DMwere diag-
nosed by a physician for at least 6months prior to their recruitment, and
were on oral antihyperglycemic agents and/or insulin medication.
Newly diagnosed persons with hyperglycemia (FPG N 7.0 mmol/l)
were also included in the diabetic group (see below). All participants
were on unrestricted diets. Any person suffering from an acute disease
was excluded from the study. Pregnantwomen, patientswith Type 1 di-
abetes and history of cancer were excluded. All participants were tested
for renal, hepatic and cardiovascular diseases, and participants with
clinically signiﬁcant renal, hepatic and cardiovascular diseases were ex-
cluded. The participants did not have any history of chronic alcohol con-
sumption. Underweight persons (body mass index, BMI b 18.5 kg/m2)
were also excluded.
The Institutional Review Board (IRB) of Harvard Biotech BD Ltd.
(Dhaka, Bangladesh) reviewed and approved the study. An informed
consent form to participate in the study was signed by each participant.
2.2. Laboratory Tests, Physical Examination and Socio-Medical History
Laboratory tests were performed using biochemical assay kits from
Linear Chemicals S.L. (Barcelona, Spain) and an automatic biochemistry
analyzer from SinnowaMedical Science& Technology Co., Ltd. (Nanjing,
Jiangsu, China; Model: Sinnolab MT 5000, Version 5.00). The diabetes
status of each participant (diabetes patients and healthy controls) was
conﬁrmed by measuring fasting (at least 10 h) plasma glucose (FPG).
An FPG level N 7.0 mmol/l (126 mg/dl), was considered diagnostic for
diabetes (American Diabetes Association, 2014). Any newly diagnosed
diabetes patient (FPG N 7.0 mmol/l) was included in the diabetic
group. All participants were also subjected to serum biochemical tests
for cholesterol, low-density lipoproteins (LDL), high-density lipoprotein
(HDL), triglycerides, creatinine and alanine aminotransferase (ALT).
Height and weight of each participant were measured to calculate the
BMI deﬁned as weight in kg divided by the square of height in meter
(kg/m2). Participantswere asked for thehistory of alcohol consumption.
Medical history was used to discover participants with kidney, liver and
heart diseases. The status of cardiovascular disease was also evaluated
by measuring blood pressure.
2.3. Homogenization of Stool
The supernatant of a homogenized stool suspensionwas used for al-
kaline phosphatase (AP) assay. A small amount of fresh stool (mgs)was
measured and then the ‘stool dilution buffer’ (10 mM Tris–HCl, pH 8.0,
1 mM magnesium chloride, 10 μM zinc chloride) at a deﬁned ratio
was added. Usually, 50 μl of stool dilution buffer was added to 1 mg of
stool. The sample was vigorously vortexed to prepare a homogenized
stool suspension, which was then centrifuged at 10,000 ×g for 20 min,
and the supernatant containing AP was collected and assayed for AP
concentration. It is to point out that stool suspended in water shows a
bit lower AP activity compared to stool suspended in stool dilution
buffer.2.4. Alkaline Phosphatase Assay
The stool supernatant was assayed for alkaline phosphatase (AP)
following an established protocol using the automatic biochemistry
analyzer mentioned above (Nanjing, Jiangsu, China). In brief, 20 μl of
supernatant was added to 1 ml of enzyme assay buffer (1.25 M
diethanolamine (DEA) buffer, pH 10.2, 0.6 mM magnesium chloride)
containing 10 mM p-nitrophenyl phosphate (pNPP), and the reaction
mixture was incubated for one min at 37 °C followed by measuring
the AP concentration by the analyzer pre-calibrated with AP standards.
To determine the major isoform among stool APs, prior to assaying for
AP activity an aliquot of stool sample was treated for 10 min with L-
phenylalanine (L-Phe, 10 mM ﬁnal conc.), a speciﬁc inhibitor of IAP,
and another aliquot with L-homoarginine (L-Arg, 10 mM ﬁnal conc.),
a speciﬁc inhibitor of tissue-nonspeciﬁc alkaline phosphatase (TNAP)
(Kaliannan et al., 2013; Sergienko et al., 2009). Each aliquot treated
with an inhibitor was then mixed with the reaction buffer containing
an equal concentration (10mM) of the respective inhibitor, and assayed
for AP activity using the analyzer. Because most of the AP activity in
stool is due to IAP (see Results) the stool AP values are expressed as
units of IAP/g stool. All AP assays were performed by a single laboratory
technologist who was blinded to the diagnoses of participants.
2.5. Statistical Analysis
The SAS System (SAS Institute, Cary, North Carolina) was used for
statistical analysis. Mean and standard errors were calculated for
T2DM cases and non-T2DM controls stratiﬁed by sex. The correlation
between IAP levels and various risk factors for T2DM was assessed via
Pearson correlation coefﬁcient stratiﬁed by sex and T2DM status
(T2DM patients or non-T2DM controls). Mean differences in IAP levels
between T2DM cases and non-T2DM controls were assessed via linear
regression models controlling for the effects of age, sex, FPG and BMI
on IAP levels and T2DM status. The statistical signiﬁcance of the vari-
ance associated with independent variables were assessed from sum
of square III using GLM procedure in SAS. Multiple logistic regression
using Proc Logist procedure in SAS assessed association between
T2DM cases with independent risk factors including IAP. Regression co-
efﬁcients and odds ratios were used to express the independent risk
contribution of IAP to T2DM status. The statistical signiﬁcance of the dif-
ference between two groupswas determined using unpaired two-tailed
Student's t-Test. The difference between two groups was considered
signiﬁcantwhen the p valuewas b 0.05. Student's t-Test was performed
using Microsoft Excel program. Post-hoc statistical power analysis of
two independent groups was performed using an online program
(http://clincalc.com/Stats/Power.aspx).
2.6. Role of the Funding Source
The funding source (Harvard Biotech BD Ltd., Dhaka, Bangladesh)
played no role in the development of theory and study design. Harvard
Biotech BD Ltd. was also not involved in the collection, analyses, and in-
terpretation of data, or writing and submission of the manuscript. The
corresponding author had full access to all the data in the study, and
took the decision for publication of the data.
3. Results
3.1. Stool Alkaline Phosphatase Activity Is Mostly Due to Intestinal Alkaline
Phosphatase
Intestinal alkaline phosphatase (IAP) knockout (Akp3−/−) mice de-
velop T2DM (Kaliannan et al., 2013), and based on this observation
we hypothesized that IAP might play a protective role against T2DM
in humans. Accordingly, we decided to measure IAP concentrations in
the stools of diabetic and control non-diabetic healthy people. However,
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kaline phosphatases (APs) with T2DM in humans, we ﬁrst decided to
determine the nature of major AP isoform in the stools of both diabetic
and control healthy populations. We performed AP assays on individual
aliquots of a stool sample in presence of L-phenylalanine (L-Phe, a spe-
ciﬁc inhibitor of IAP) as well as L-homoarginine (L-Arg, a speciﬁc inhib-
itor of TNAP). L-Phe inhibited approx. 80% of the AP activity in the stool
of total healthy population, and the inhibition was approx. 70% in total
diabetic population, however, the difference was statistically signiﬁcant
(p = 0.00014) (Fig. 1a). On the other hand, L-Arg had no inhibitory
effect on the stool AP activity of either group. Gender-matched distribu-
tions also showed similar AP inhibitory effect of L-Phe inmales (Fig. 1b)
and females (Fig. 1c) of both control and diabetic groups. This result in-
dicates that most of the stool AP activity is due to IAP, and accordingly,
we decided to refer stool AP as IAP in the following sections as it is
applicable.
3.2. Patients with Type 2 Diabetes Mellitus (T2DM) Have Low Levels of IAP
in Their Stool
We determined the levels of IAP in the stools of 202 T2DM patients
(63 males, 139 females) and 445 non-diabetic healthy controls (114
males, 331 females). We recruited participants from all age groups
(see below), and there was no signiﬁcant difference in age between re-
spective control and diabetic groups. Table 1 shows a few important
physical and biochemical characteristics of participants, such as age,
weight, height, body mass index (BMI), systolic and diastolic blood
pressures, and levels of serum creatinine, cholesterol, HDL-cholesterol,
LDL-cholesterol, triglycerides, alanine aminotransferase (ALT) and
fasting plasma glucose (FPG).
IAP concentrations in the stools of entire non-diabetic healthy con-
trol and diabetic populations are shown in Fig. 2a. Compared to healthy
controls, T2DM patients have approximately 47.6% less IAP in their
stools and the difference is highly signiﬁcant (67.4 +/− 3.2 vs
35.3 +/− 2.5 U/g stool, respectively; p = 5.6E-10). Also, sex-
dependent distributions show similar reduction in IAP levels in male
and female diabetes patients (Fig. 2a). Compared to healthy males, dia-
betic males have 51.4% less IAP (57.1 +/− 4.5 vs 27.7 +/− 3.2 U/g
stool, respectively; p= 0.000011). Similarly, in comparison to healthy
females, diabetic females have 45.4% less IAP (71.0 +/− 4.0 vs
38.8 +/− 3.3 U/g stool, respectively; p = 0.0000016). Healthy control
males have the IAP levels 19.6% less than the healthy females, however,
the difference is not signiﬁcant (p= 0.061). On the other hand, the dia-
betic males have 28.6% lower IAP levels compared to diabetic females,
and the difference is statistically signiﬁcant (p = 0.041). The above
data suggest a protective role of high IAP against T2DM.
We determined age group- and gender-matched distributions of
IAP. We observed a decreasing trend of enzyme levels with age both
in males (Fig. 2b) and females (Fig. 2c) of non-diabetic and diabetic
populations. It is apparent that compared to non-diabetic group,
T2DMpatients have approx. 35–60% lessmean stool IAP, and the differ-
ence between two respective groups is statistically signiﬁcant. The least
reduction (36.8%) in IAP level is observed in 40–49 yr. old diabeticFig. 1. Stool alkaline phosphatase activity is mostly due to intestinal alkaline phosphatase
(IAP). Stool samples of non-diabetic healthy controls and T2DM patients were homoge-
nized in a stool dilution buffer followed by centrifuging and collection of supernatant.
The supernatant was assayed for alkaline phosphatase (AP) concentrationwithout any in-
hibitors (total activity) or in presence of L-phenylalanine (L-Phe), a speciﬁc inhibitor of IAP
as well as in presence of L-homoarginine (L-Arg), a speciﬁc inhibitor of tissue nonspeciﬁc
alkaline phosphatase (TNAP), using an automatic biochemistry analyzer. (a) Effects of AP
inhibitors on the AP activity in the stools of total control and diabetic populations.
(b) Effects of AP inhibitors on theAP activity in the stools ofmale control and diabetic pop-
ulations. (c) Effects of AP inhibitors on the AP activity in the stools of female control and
diabetic populations. Statistics: Values are expressed as mean +/− SEM. Statistical signif-
icance of the difference between two respective groups was tested using the unpaired
two-tailed Student's t-Test. p b 0.05 is considered signiﬁcant. **, p b 0.01; ***, p b 0.001.females, whereas the highest reduction (59.0%) is evidenced in 60–
70 yr. old male diabetes patients. Although it appears that IAP levels
decrease with age, however, we observed no statistically signiﬁcant
Table 1
Characteristics of healthy control participants and T2DM patients.
Type of participants Total participants Males Females
Healthy T2DM Healthy T2DM Healthy T2DM
No. of participants 445 202 114 63 331 139
Age of participants (yr.) 47.1 +/− 0.4 47.6 +/− 0.7 48.7+/− 0.8 50.9 +/− 1.2 46.7 +/− 0.5 46.0 +/− 0.8
Weight (kg) 59.3 +/− 0.5 59.6 +/− 0.7 65.0 +/− 0.9 65.7 +/− 1.3 57.3 +/− 0.6 56.9 +/− 0.8
Height (m) 1.52 +/− 0.00 1.52 +/− 0.01 1.62 +/− 0.01 1.61 +/− 0.01 1.48 +/− 0.00 1.48 +/− 0.01
BMI (kg/m2) 25.7 +/− 0.2 26.0 +/− 0.3 24.7 +/− 0.3 25.5 +/− 0.5 26.1 +/− 0.2 26.2 +/− 0.4
Systolic blood pressure (mm Hg) 134.2 +/− 1.1 137.3 +/− 1.5 134.4 +/− 1.7 133.3 +/− 2.5 134.2 +/− 1.4 139.0 +/− 1.8
Diastolic blood pressure (mm Hg) 78.9 +/− 0.6 80.1 +/− 0.8 80.0 +/− 1.1 80.8 +/− 1.4 78.5 +/− 0.7 79.8 +/− 1.0
Creatinine (mg/dl) 0.98 +/− 0.15 0.9 1 +/− 0.02 0.89 +/− 0.03 0.95 +/− 0.03 1.01 +/− 0.20 0.89 +/− 0.03
Cholesterol (mg/dl) 162.7 +/− 1.3 172.5 +/− 2.2*** 160.3 +/− 2.6 164.4 +/− 4.1 162.7 +/− 1.3 176.2 +/− 2.5***
HDL (mg/dl) 38.1 +/− 0.4 38.8 +/− 0.5 36.7 +/− 0.7 38.6 +/− 0.9 38.6 +/− 0.4 38.8 +/− 0.6
LDL (mg/dl) 94.6 +/− 1.0 102.2 +/− 2.0*** 93.2 +/− 2.5 94.5 +/− 4.0 95.0 +/− 1.1 105.7 +/− 2.2***
Triglycerides (mg/dl) 152.2 +/− 2.3 159.4 +/− 3.8 153.5 +/− 5.9 162.3 +/− 7.6 151.7 +/− 2.4 158.1 +/− 4.3
ALT (U/l) 44.8 +/− 0.9 47.7 +/− 1.7 46.9 +/− 2.4 49.0 +/− 2.8 44.1 +/− 0.8 47.1 +/− 2.1
FPG (mmol/l) 4.4 +/− 0.0 8.2 +/− 0.2*** 4.4 +/− 0.1 8.3 +/− 0.4*** 4.4 +/− 0.0 8.2 +/− 0.3***
The participants were recruited from a suburb of Dhaka, Bangladesh. All participants were on overnight (10 h) fasting and investigated for all the physical and biochemical tests described
above. Statistics: Values are expressed asmean+/− SEM. Statistical signiﬁcance of thedifference between two respective groupswas tested using the unpaired two-tailed Student's t-Test.
p b 0.05 is considered signiﬁcant. ***, p b 0.001.
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3.3. IAP Levels Are Low in T2DM Patients at All Percentile Points
Taking in consideration of any inﬂuence of ‘outliers’ (a few extreme-
ly high or lowvalues compared to themost other values) on the average
(mean) values of IAP levels as shown above (see Fig. 2a), we further
veriﬁed the difference in IAP levels of diabetic and non-diabetic groups
at different percentile points. We evaluated the percentile distribution
of IAP values in 202 T2DM and 445 healthy controls.We organized indi-
vidual IAP values from each group (diabetic or non-diabetic) from the
lowest to the highest, and then calculated the average IAP value within
each 10 percentile divisions. It is apparent that at all percentile points
IAP values are less in T2DM patients compared to the healthy popula-
tion, and the difference is highly signiﬁcant (Fig. 3). The percentile dis-
tribution of IAP levels conﬁrms that T2DM patients, indeed, have
lower levels of IAP compared to their counterparts. This distribution fur-
ther conﬁrms that IAP plays a protective role against diabetes.
3.4. IAP Deﬁciency Is Associated with T2DM
Pearson correlation coefﬁcient analysis showed no correlation be-
tween the IAP level and age, gender, FPG, BMI, ALT, serum creatinine,
blood pressure and lipid parameters (Table 2). A generalized linear re-
gression model predicted a strong association of IAP with T2DM
(Table 3). It also predicted mild association of IAP with age validating
the observation of decreasing trend of IAP with age (see Fig. 2b & c).
We performed multiple logistic regression analyses controlling for age,
FPG, BMI, ALT, serum creatinine, blood pressure and lipid parameters.
The data showed an independent inverse relationship between the
IAP level and diabetes status (Table 4). With each 25 U/g decrease in
stool IAP, there is a 35% increased risk of diabetes. We conclude that
IAP deﬁciency is associated with diabetes independent of other known
diabetes risk factors, and a high IAP level is protective against T2DM.
3.5. Hyper- and Normo-Glycemic T2DM Patients Have Similar Levels of
Stool IAP
T2DM patients on rigorous antidiabetic medications and life-style
changes very often achieve normoglycemic status (FPG b 7.0 mmol/l).
We were interested to knowwhether the glycemic status of diabetes
patients has any effect on the stool IAP level. We observed that both
hyperglycemic (FPG N 7.0 mmol/l) and normoglycemic diabetes pa-
tients have similar levels of IAP in their stools, and the difference invalues of respective groups is not statistically signiﬁcant (Total pop-
ulation: 37.7 +/− 3.4 vs 32.0 +/− 3.8 U/g stool, respectively, p =
0.26; Male: 29.6 +/− 4.4 vs 25.1 +/− 4.6 U/g stool, respectively,
p = 0.50; Female: 41.3 +/− 4.4 vs 35.2 +/− 5.2 U/g stool, respec-
tively, p = 0.38). These data suggest that glycemic status and/or
antidiabetic medications do not affect IAP concentrations.
3.6. Obese People with High IAP Do Not Develop T2DM
It is well recognized that overweight (BMI N 25.0 kg/m2) and
obese (BMI N 30.0 kg/m2) populations are more vulnerable for devel-
oping T2DM than the population with normal weights (BMI b 25.0–
18.5 kg/m2). We categorized the T2DM patients as well as healthy
controls of this study in two groups, one with BMI N 25.0 kg/m2 and
the other having BMI b 25.0 kg/m2. Fig. 4 is a graphical presentation of
IAP levels in high- and low-BMI groups. It is evident that both groups
of diabetic participants have signiﬁcantly lower amounts of IAP com-
pared to their healthy counterparts. It is also obvious that an obese or
overweight person with high IAP belongs to the non-diabetic control
group, but not to the diabetic group. These data suggest that IAP plays
a protective role against the development of T2DM irrespective of BMI.
3.7. The Majority of Population Has the Incipient Metabolic Syndrome
The ‘overt’ metabolic syndrome is deﬁned as co-existence of 3
out of 5 criteria encompassing obesity (BMI N 30.0 kg/m2), hyper-
glycemia (FPG N 5.5 mmol/l), hypertension (systolic blood
pressure N 130 mm Hg or diastolic blood pressure N 85 mm Hg),
hypertriglyceridemia (N150 mg/dl) and low high-density lipopro-
tein (HDL) (b 40 mg/dl for males or b 50 mg/dl for females)
(Huang, 2009). It is to point out that contributions of total choles-
terol and LDL-cholesterol are not considered in deﬁning the meta-
bolic syndrome. We have previously shown that IAP deﬁciency
causes the metabolic syndrome in mice (Kaliannan et al., 2013). There-
fore, we predict that the association of IAP deﬁciency with T2DM in
humans might be useful to isolate the people having ‘the incipient
metabolic syndrome’ who are healthy persons vulnerable to develop
the metabolic syndrome due to IAP deﬁciency. People with ‘the incipi-
ent metabolic syndrome’ would include the persons having ‘incipient’
diabetes, heart disease, nonalcoholic fatty liver disease, hypertension,
and other metabolic disorders. We observed that the average IAP level
in healthy population is approx. 67.4 +/− 3.2 U/g stool (see Fig. 2),
and hence we deﬁne that, under the conditions of AP assay described
here, a healthy person having IAP level less than 65.0 U/g stool should
be considered as having ‘the incipient metabolic syndrome’ that
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subjects 299 people have IAP level b 65.0 U/g stool, which means that
approx. 67.2% of the healthy population have ‘the incipient metabolic
syndrome’. We also noticed that 39.8% of control participants have IAP
levels that are less than the average IAP level in diabetes patients
(35.0 U/g stool), and we consider these persons have ‘the severe incip-
ient metabolic syndrome’ and are extremely vulnerable to develop the
metabolic syndrome within the near future.4. Discussion
Type 2 diabetes mellitus (T2DM) is a major global health problem.
Based on our previous observation that IAP deﬁciency leads to T2DM
in mice (Kaliannan et al., 2013), we hypothesized that humans with
high IAP levels might be protected from T2DM, and indeed, the present
study validated our hypothesis. We found that diabetes patients of all
age groups have less amounts of IAP in their stool compared to their
healthy counterparts. The study established that IAP deﬁciency is
associated with T2DM, and a loss of 25 U/g IAP increases the risk of
developing T2DM by 35% (see Figs. 2 & 3, Tables 3 & 4). We discovered
a protective role of high IAP against diabetes irrespective of obesity
(see Fig. 4).
In the context of confounding factors affecting the AP levels in stool,
we presumed that the stool AP activity could be due to different human
AP isoforms as well as bacterial AP. However, we found that most of the
human stool AP activity is due to IAP (see Fig. 1). We believe that the
difference between total AP and IAP might represent microbial AP
because the activity of TNAP isoform is very low.
It is worthy to note that IAP excreted in stool reﬂects the balance
among production, digestion and degradation of IAP in the intestine,
and these processes could be modulated by different factors, especially
diets (Lallès, 2010; Lalles, 2014). This study was performed on partici-
pants on unrestricted diets. We believe, it is unlikely that diets had
any signiﬁcant effect on these data because the sample sizes were rela-
tively large (achieved 100% statistical power) and even 40% of the con-
trol healthy participants with ‘the severe incipientmetabolic syndrome’
(see above) had IAP values less than the average IAP value in T2DM
patients. However, we believe, it will be interesting to include dietary
questionnaires in future studies for evaluating any possible diet-
induced IAP deﬁciency.
We observed a distinctly visible decreasing trend of IAP with age
(Fig. 2b & c), however, the difference between the younger and older
groups of the same population (T2DM patients or healthy controls)
was not statistically signiﬁcant that, we believe, could probably be due
to small number of sample size for each age-group. We anticipate that
it will require larger sample size for each age group to establish any
probable inverse relationship with IAP levels and age. It is noteworthy
that the generalized linear regression model predicted an inverse
relationship of age with IAP levels (see Table 3).Fig. 2. Patients with type 2 diabetes mellitus (T2DM) have low levels of intestinal alkaline
phosphatase (IAP) in their stool. Stool samples of healthy participants and T2DM patients
were assayed for IAP concentration using an automatic biochemistry analyzer (see Fig. 1).
(a) IAP concentrations in the stools of total non-diabetic healthy control and diabetic pop-
ulations. (b) Age-dependent distribution of IAP concentrations in the stools ofmale control
and diabetic populations. (c) Age-dependent distribution of IAP concentrations in the
stools of female control and diabetic populations. Statistics: Values are expressed as
mean +/− SEM. Statistical signiﬁcance of the difference between two groups was tested
using the unpaired two-tailed Student's t-Test. p b 0.05 is considered signiﬁcant.
*, p b 0.05; **, p b 0.01; ***, p b 0.001. The post-hoc statistical power analyses revealed
thepowers for respective total,male and female groups to be 100%, 100%and100%, respec-
tively, validating the adequacy of power (conventionally, N 80% power atα=0.05) for re-
spective sample sizes. Percentage loss of IAP in T2DM patients compared to healthy
controls: Total, 47.6%; male, 51.4%; female, 45.4%. The average IAP level is 19.6% less in
healthy control males compared to healthy females, however, the difference is not signif-
icant (p=0.061). T2DMmales have 28.6% less IAP compared to T2DMfemales, and thedif-
ference is signiﬁcant (p=0.041). The difference in IAP values between younger and older
groups of the same population (diabetic or non-diabetic) is not statistically signiﬁcant.
Fig. 3. IAP levels are low in T2DM patients at all percentile points. Individual IAP values
from each group (Healthy Controls or T2DM Patients) were arranged from the lowest to
the highest, and then the average IAP value within each 10th percentile was calculated
(n= 20within each 10th percentile for T2DM Patients, and n= 44within each 10th per-
centile for Healthy Controls). Average values for corresponding percentiles are plotted.
Statistics: Values are expressed asmean+/− SEM. Statistical signiﬁcance of the difference
between two respective groupswas tested using the unpaired two-tailed Student's t-Test.
p b 0.05 is considered signiﬁcant. ***, p b 0.001. Note: Only the values in ﬁrst and last 10
percentile divisions will be greatly affected if an ‘outlier’ (a few extremely high or low
values, compared to themost other values, affecting themean value) is present. The values
within 10th and 90th percentiles are real, not affected by outliers.
Table 3
A generalized linear regression model predicts an association of IAP with T2DM.
Source DF Type III SS F Value Pr N F
Diabetes 1 81665.00 23.30 b0.0001
Sex 1 12309.33 3.51 0.0614
FPG (mmol/l) 1 180.46 0.05 0.8206
BMI (kg/m2) 1 5335.29 1.52 0.2177
Age 1 23707.51 6.76 0.0095
The model predicts a strong association of IAP with T2DM. It also predicts a mild associa-
tion of IAP with age (IAP level gradually decreases with age; see Fig. 2b & c).
2021M.S. Malo / EBioMedicine 2 (2015) 2016–2023We found that healthy males have approximately 19.6% less stool
IAP compared to healthy females, however, the difference is not statis-
tically signiﬁcant. On the other hand, T2DM males have 28.6% less IAP
compared to T2DM females, and the difference is signiﬁcant (p =
0.041). This observation indicates that, in the context of developing
T2DM, males can accept more loss of IAP compared to females. We
speculate that a relatively sedentary life or other risk factors may
make females more vulnerable to T2DM even when they have higher
levels of IAP.
Obesity or high BMI has long been considered a contributing factor
to T2DM, however, this study makes a striking revelation that if a
person's IAP level is high then the person is resistant to develop T2DM
even if the person is obese (see Fig. 4). In the context of childhood
obesity and associated metabolic syndrome (Steinberger, 2003), it will
be interesting to investigate the levels of IAP in these children. We
anticipate that IAP deﬁciency might be an early event of life.
Antidiabetic therapy aims to achieve normoglycemic status, and we
therefore, evaluated the effects of glycemic status on stool IAP levels
(see Results). We observed that IAP levels are not signiﬁcantly different
in hyperglycemic and normoglycemic diabetes patients, whichTable 2
Pearson correlation coefﬁcients showingno correlation of IAP levelswith different risk fac-
tors of T2DM.
Type of participants Male Female









Age −0.192 −0.221 −0.08 −0.131
BMI −0.024 0.088 0.085 0.008
Creatinine −0.013 −0.069 0.07 0.055
Total cholesterol 0.267 −0.132 0.004 0.127
HDL-cholesterol 0.101 −0.007 0.005 0.206
LDL-cholesterol 0.176 −0.130 −0.014 0.080
Triglycerides 0.138 0.014 −0.007 0.074
ALT 0.156 0.107 −0.065 −0.013
FPG −0.076 0.039 0.05 −0.014
Systolic blood pressure 0.169 −0.257 −0.031 −0.153
Diastolic blood pressure −0.040 −0.059 0.039 −0.060
A Pearson correlation coefﬁcient close to +1 or−1 indicates that the two variables are
highly correlated (positively or negatively, respectively). A correlation coefﬁcient between
0 and +0.30 or between 0 and−0.30 was considered of having no correlation between
the two variables.indicates that glucose levels and/or antidiabetic drugs do not play any
signiﬁcant role in modulating IAP levels.
We observed that themajority (approx. 65%) of the healthy popula-
tion has ‘the incipient metabolic syndrome’ (see Results). People with
‘the incipient metabolic syndrome’ would also include people with
‘the pre-metabolic syndrome’ exhibiting at least one criterion of the
metabolic syndrome (Kaliannan et al., 2013; Huang, 2009). We believe,
the observed 65% prevalence rate of ‘the incipient metabolic syndrome’
in this study is in concordance with the 71% prevalence rate of the pre-
metabolic syndrome in Saudi soldiers (Al-Qahtani and Imtiaz, 2005).
Also, it was reported that 68–81% of Pakistani people have low levels
of HDL-cholesterol, one criterion of the metabolic syndrome (Basit
and Shera, 2008). We calculated that approx. 40% of healthy subjects
have amounts of IAP that are less than the average IAP value of the
diabetic group (35.0 U/g stool). We predict that these people have ‘the
severe incipient metabolic syndrome’ and are extremely vulnerable to
develop T2DM or other metabolic disorders within a few years (see Re-
sults). Interestingly, the prevalence rate of ‘overt’metabolic syndrome is
also 40% (Kaliannan et al., 2013).We also observed that a few T2DMpa-
tients (approx. 15%) have stool IAP level N 67.0 U/g (the average value of
healthy controls), and this observation prompted us to speculate that ei-
ther IAP is not associatedwith the pathogenesis of T2DM in these specif-
ic patients or a persistent loss of IAP from a previously high level might
also lead to T2DM. A loss of approx. 50% IAP activitymight be signiﬁcant
to precipitate T2DM as diabetes patients on average have approx. 50%
less IAP compared to their healthy counterparts (see Fig. 2).
T2DM is diagnosed by hyperglycemia (FPG N 7.0 mmol/l), which is
associated with the established T2DM or with the terminal stage of de-
velopment of T2DM. Therefore, it is obvious that measuring FPG cannot
be used to predict years in advance whether the person have incipient
diabetes. Currently, there is no protocol for predicting incipient diabe-
tes. We anticipate that diagnosis and treatment of incipient diabetes
will be the critical steps to control the devastating global pandemic of
T2DM. This study establishes a protocol for diagnosing incipientTable 4
Multiple logistic regression analyses predict an association of IAP deﬁciency with T2DM.
Explanatory variables Logistic coefﬁcients
per unit change
Odds ratio (95% CI)
Age (yr.) 0.0226 1.023 (0.993–1.054)
Body mass index (BMI, kg/m2) 0.0466 1.048 (0.986–1.114)
Creatinine (mg/dl) −0.0166 0.983 (0.847–1.142)
Total cholesterol (mg/dl) 0.00183 1.002 (0.984–1.020)
HDL-cholesterol (mg/dl) −0.0599 0.942 (0.900–0.985)
LDL-cholesterol (mg/dl) 0.0206 1.021 (1.001–1.041)
Triglycerides (mg/dl) 0.00473 1.005 (0.998–1.011)
ALT (U/l) 0.00944 1.009 (0.998–1.021)
Systolic blood pressure (mm Hg) −0.00012 1.000 (0.984–1.016)
Diastolic blood pressure (mm Hg) −0.0139 0.986 (0.958–1.015)
FPG (mmol/l) 1.3563 3.882 (2.972–5.070)
IAP (U/g stool) −0.0145 0.986 (0.978–0.993)
With each U/g decrease in stool IAP level there is a 1.4% increase in the odds of diabetes
diagnosis. For example, if there is 25U/g decrease in IAP level therewill be a 35% increased
risk of diabetes. Statistics: Proc Logist procedure (SAS) was used for multiple logistic re-
gression analyses determining association between T2DM with independent risk factors
including IAP.
Fig. 4.Ahigh level of IAP is protective against T2DM irrespective of bodymass index (BMI).
Stool samples of healthy participants and T2DM patients were assayed for IAP concentra-
tion using an automatic biochemistry analyzer (see Fig. 1). The healthy controls as well as
T2DMpatients were categorized in two groups, one with high BMI (N 25.0 kg/m2) and the
other having low BMI (b 25.0 kg/m2). Statistics: Values are expressed as mean +/− SEM.
Statistical signiﬁcance of the difference between two groups was tested using the
unpaired two-tailed Student's t-Test. p b 0.05 is considered signiﬁcant. *, p b 0.05;
**, p b 0.01; ***, p b 0.001. Note: There was no signiﬁcant difference in IAP levels be-
tween high- and low-BMI groups of healthy controls as well as between high- and
low-BMI groups of diabetes patients.
2022 M.S. Malo / EBioMedicine 2 (2015) 2016–2023diabetes, the metabolic syndrome and other metabolic disorders based
on regular monitoring of stool IAP, deﬁned here as ‘temporal IAP
proﬁling’.
This study points towards a possibility of using oral IAP supplemen-
tation as a therapeutic approach for preventing/treating incipient diabe-
tes and/or other overt or incipient metabolic diseases. We believe that
any therapeutic aim should be at least to preserve/restore the normal
level of IAP in stool (approx. 65.0 U/g stool). Another therapeutic ap-
proach might involve up-regulation of IAP by small molecules, such as
short-chain fatty acids (as sodium butyrate and propionate), thyroid
hormone, curcumin, omega-3 fatty acid, etc. (Meng et al., 1999; Malo
et al., 2004; Ghosh et al., 2014; Kaliannan et al., 2015). Mahmood et al.
(2003) have shown that corn oil feeding increases IAP secretion in
rats, which we believe, might be a physiological response to prevent
the high-fat diet-associated endotoxemia (Kaliannan et al., 2013). We
anticipate that it will be critically important to decipher the mecha-
nisms of IAP deﬁciency for understanding the pathophysiology of
T2DM. Dysbiosis has been implicated in the pathogenesis of the meta-
bolic syndrome and diabetes (Kaliannan et al., 2013; D'Aversa et al.,
2013; Tilg and Moschen, 2014; Parekh et al., 2015), and based on this
observationwe postulate that dysbiosismight be responsible for IAP de-
ﬁciency that ultimately leads to the metabolic syndrome and diabetes.
We believe, future projects should focus on ﬁnding out whether any
genetic, environmental and/or nutritional factor is involved in IAP
deﬁciency.
Wewould like to point out that a previous study by Kim et al. (2013)
reported 6.5% higher serum alkaline phosphatase activity in patients
with the metabolic syndrome compared to healthy counterparts. We
believe, the difference is within experimental error (conventionally,
+/−10% variation from the mean value), and hence total serum
alkaline phosphatase levels cannot be used to predict an individual
vulnerability to the metabolic syndrome. Also, total serum alkaline
phosphatase activity serves as a non-speciﬁc marker of inﬂammation
(Lalles, 2014), and the intestinal contribution to total serum AP activity
is less than 5% (Matsushita et al., 2002).
Intestinal alkaline phosphatase (IAP) is a membrane-bound glyco-
protein that is exclusively expressed in villus-associated enterocytes of
proximal small intestine and hence recognized as an enterocyte differ-
entiation marker (Lalles, 2014; Malo et al., 2006). Its regulation andfunction have been extensively reviewed (Lallès, 2010; Lalles, 2014;
Estaki et al., 2014; Sharma et al., 2014; Buchet et al., 2013; Vaishnava
and Hooper, 2007). From the enterocytes the enzyme is bidirectionally
secreted into the intestinal lumen as well as the systemic circulation
(Eliakim et al., 1991). IAP in the intestinal lumen travels downwards
from the proximal small intestine to the distal large intestine and then
excreted with stool (Malo et al., 2010).
Physiologically, IAP exerts two very important functions with re-
spect to its existence in the luminal bacterial environment; ﬁrstly, it
maintains the normal homeostasis of intestinal microbiota, and second-
ly, it detoxiﬁes bacterial toxins. We have shown that IAP knockout mice
harbor fewer bacteria compared to its wild-type littermates (Malo et al.,
2010), and IAP promotes the gut bacterial growth by reducing the con-
centrations of intestinal luminal nucleotide triphosphates that have
toxic effect on bacterial growth (Malo et al., 2014). We and others
have shown that IAP detoxiﬁes various bacterial toxins, such as lipo-
polysaccharides (LPS), CpG DNA, ﬂagellin and uridine diphosphate
(UDP), and IAP probably destroys these targets by dephosphorylation
(phosphohydrolysis) (Bentala et al., 2002; Chen et al., 2010; Moss
et al., 2013). Further, IAP limits fat absorption (Narisawa et al., 2003)
and maintains the gut mucosal integrity (Hamarneh et al., 2015).
Pharmacologically, oral supplementation of IAP prevents antibiotic-
induced susceptibility to enteric pathogens such as Salmonella
Typhimurium, and Clostridium difﬁcile (Malo et al., 2010; Alam et al.,
2014).We have shown that oral IAP supplementation not only prevents
but also cures the high fat diet-induced metabolic syndrome in mice
(Kaliannan et al., 2013). IAP supplementation have been shown to
have efﬁcacious values in treating colitis in humans and mice (Lukas
et al., 2010; Ramasamy et al., 2011; Whitehouse et al., 2010), and peri-
tonitis in animal models (van Veen et al., 2005; Ebrahimi et al., 2011).
We have previously shown that IAP deﬁciency causes T2DM inmice
(Kaliannan et al., 2013), and here we demonstrate that IAP deﬁciency is
associatedwith T2DM in humans.We strongly believe that IAP deﬁcien-
cy also causes T2DM in humans, and to conﬁrm this hypothesis, we
anticipate, it will require a long-term cohort studymonitoring ‘temporal
IAP proﬁles’ and incidence rates of T2DM among the people with
‘incipient diabetes’ and other healthy populations.
5. Conclusions
In conclusion, this study links IAP deﬁciency in stool with T2DM, and
shows that a high level of IAP is protective against diabetes irrespective
of obesity. The study also provides a tool for diagnosing ‘the incipient
metabolic syndrome’ including ‘incipient diabetes’ based on ‘temporal
proﬁling of IAP’.
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